Sanofi receives EU approval for next-generation rabies vaccine
In short
Sanofi has secured official European Union authorization to distribute its next-generation rabies vaccine. The regulatory endorsement clears the path for the pharmaceutical manufacturer to supply the advanced immunization within the bloc. By introducing this updated formulation, the company aims to support ongoing public health measures against the deadly viral infection across European territories.
Key points
- Sanofi can now commercially supply its next-generation rabies vaccine throughout the Euro…: Sanofi can now commercially supply its next-generation rabies vaccine throughout the European Union.
- The approval marks an important expansion of available medical options for preventing rab…: The approval marks an important expansion of available medical options for preventing rabies infections.
- European health authorities have officially sanctioned the pharmaceutical company's advan…: European health authorities have officially sanctioned the pharmaceutical company's advanced vaccine formulation.